Vertex tightens CF focus as promising flu candidate out-licensed to Janssen
This article was originally published in Scrip
Executive Summary
J&J subsidiary Janssen has agreed to pay $30m upfront to Vertex Pharmaceuticals for global development and commercialization rights to a novel influenza candidate with a mechanism of action distinct from neuraminidase inhibitors, the current standard of care for the treatment of flu.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.